Drug reference

zoledronate

Bisphosphonate · Antiresorptive agent

BisphosphonateAntiresorptive agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Not yet extracted

Indications

Paget diseasetreatment and prevention of osteoporosishypercalcemia of malignancyadjunctive treatment of bone metastases from solid tumorsosteolytic lesions of multiple myelomaHypercalcaemiaBony metastasisOsteolytic lesionsPaget’s diseasePostmenopausal osteoporosis (when oral alendronate/risedronate are not tolerated)For patients whose bone health is compromised by breast cancer therapy (especially estrogen-deprivation agents), as a bone-strengthening agentAssociated with decreased breast cancer recurrence, especially in boneAdministered regularly for metastatic bone disease to reduce skeletal morbidityHumoral Hypercalcemia of MalignancyHypercalcemia in multiple myelomaPrevent bone-related complications in multiple myeloma

Dosing

Adult: For osteoporosis, 5 mg annually intravenously. For hypercalcemia of malignancy, multiple myeloma, or bone metastasis, 4 mg intravenously over at least 15 min. For Paget disease, a single 5-mg intravenous infusion.